Canaccord Genuity Initiates Coverage On DICE Therapeutics with Buy Rating, Announces Price Target of $71
Portfolio Pulse from richadhand@benzinga.com
Canaccord Genuity analyst Edward Nash initiates coverage on DICE Therapeutics (NASDAQ:DICE) with a Buy rating and announces a price target of $71.
May 22, 2023 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity initiates coverage on DICE Therapeutics with a Buy rating and a price target of $71.
The initiation of coverage by Canaccord Genuity with a Buy rating and a price target of $71 indicates a positive outlook for DICE Therapeutics. This news is likely to attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100